Paul J Nestel Selected Research

Paul J Nestel Research Topics

Disease

15	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018 - 01/2007
11	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 11/2003
10	Insulin Resistance 01/2017 - 11/2005
7	Coronary Disease (Coronary Heart Disease) 10/2018 - 01/2002
7	Myocardial Infarction 01/2018 - 04/2005
7	Weight Loss (Weight Reduction) 01/2018 - 11/2005
5	Stroke (Strokes) 10/2018 - 04/2005
5	Unstable Angina 01/2018 - 04/2005
4	Hyperinsulinism (Hyperinsulinemia) 08/2015 - 03/2014
4	Body Weight (Weight, Body) 08/2015 - 05/2009
3	Atherosclerosis 02/2021 - 07/2007
3	Obesity 01/2021 - 04/2015
3	Inflammation (Inflammations) 01/2021 - 04/2005
3	Overweight 01/2021 - 12/2013
3	Type 2 Diabetes Mellitus (MODY) 11/2016 - 02/2007
2	Dyslipidemias (Dyslipidemia) 01/2021 - 07/2007
2	Hypertension (High Blood Pressure) 01/2018 - 02/2012
2	Neoplasms (Cancer) 01/2018 - 05/2016
2	Vascular Diseases (Vascular Disease) 01/2018 - 11/2016
2	Diabetes Mellitus 12/2017 - 11/2016
1	Metabolic Diseases (Metabolic Disease) 01/2021
1	Venous Thromboembolism 01/2018
1	Thrombophilia 01/2018
1	Heart Failure 12/2017
1	Acute Coronary Syndrome 12/2017
1	Hypotension (Low Blood Pressure) 07/2015
1	Glucose Intolerance 10/2012
1	Coronary Artery Disease (Coronary Atherosclerosis) 03/2012
1	Albuminuria 03/2011
1	Hypertriglyceridemia 08/2008

Drug/Important Bio-Agent (IBA)

12	LipidsIBA 02/2021 - 04/2005
11	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2017 - 11/2005
10	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 01/2009
7	Insulin (Novolin)FDA Link 01/2017 - 01/2009
6	Pravastatin (Pravachol)FDA LinkGeneric 01/2018 - 04/2005
5	ApolipoproteinsIBA 11/2011 - 01/2007
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2018 - 04/2005
4	Biomarkers (Surrogate Marker)IBA 11/2016 - 04/2008
3	LDL CholesterolIBA 10/2018 - 01/2007
3	HDL CholesterolIBA 10/2018 - 01/2007
3	C-Reactive ProteinIBA 01/2018 - 03/2011
3	CholesterolIBA 11/2011 - 01/2007
3	Rosuvastatin Calcium (Crestor)FDA Link 08/2008 - 02/2008
3	Lipoproteins (Lipoprotein)IBA 03/2008 - 01/2007
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 12/2008
2	Lipoprotein(a)IBA 10/2018 - 12/2013
2	fibrin fragment D (D-dimer)IBA 01/2018 - 12/2017
2	Troponin IIBA 01/2018 - 12/2017
2	HDL LipoproteinsIBA 01/2018 - 02/2008
2	Brain Natriuretic Peptide (Natrecor)FDA Link 12/2017 - 04/2008
2	Pioglitazone (Actos)FDA Link 07/2015 - 09/2014
2	3,4-dihydroxyphenylglycolIBA 09/2014 - 03/2014
2	Apolipoproteins B (ApoB)IBA 03/2008 - 01/2007
2	Triglycerides (Triacylglycerol)IBA 07/2007 - 01/2007
1	PlasmalogensIBA 01/2021
1	Methylcellulose (BFL)IBA 01/2021
1	Natriuretic PeptidesIBA 01/2018
1	FibrinIBA 01/2018
1	Cystatin CIBA 12/2017
1	SphingolipidsIBA 01/2017
1	CeramidesIBA 01/2017
1	GangliosidesIBA 01/2017
1	perindopril drug combination indapamideIBA 11/2016
1	Gliclazide (Diamicron)IBA 11/2016
1	C-PeptideIBA 08/2015
1	CarbohydratesIBA 07/2015
1	Dihydroxyphenylalanine (Dopa)IBA 03/2014
1	IsotopesIBA 10/2012
1	Uric Acid (Urate)IBA 03/2011
1	Conjugated Linoleic AcidsIBA 12/2008
1	FatsIBA 12/2008
1	Myristic Acid (Tetradecanoic Acid)IBA 12/2008
1	Apolipoprotein C-IIIIBA 08/2008
1	pro-brain natriuretic peptide (1-76)IBA 04/2008
1	Tissue Inhibitor of Metalloproteinase-1IBA 04/2008
1	Apolipoprotein B-100 (Apo B 100)IBA 03/2008
1	Apolipoproteins E (ApoE)IBA 07/2007
1	oxidized low density lipoproteinIBA 01/2007
1	Apolipoprotein A-II (Apolipoprotein A2)IBA 01/2007
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2007
1	Phytosterols (Plant Sterols)IBA 01/2007
1	SodiumIBA 11/2005
1	LeptinIBA 11/2005
1	HomocysteineIBA 11/2003
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2002

Therapy/Procedure

4	Therapeutics 10/2018 - 04/2005
1	Secondary Prevention 02/2021
1	Dietary Approaches To Stop Hypertension 02/2012